<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946279</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00020688</org_study_id>
    <secondary_id>NCI-2021-05887</secondary_id>
    <secondary_id>STUDY00020688</secondary_id>
    <nct_id>NCT04946279</nct_id>
  </id_info>
  <brief_title>Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>Improving Decision-Making Encounters in Lung Cancer (I DECide): A Low-Literacy Conversation Tool</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial refines and tests the effect of a decision aid in improving&#xD;
      decision-making in patients with non-small cell lung cancer. Patients with cancer want to be&#xD;
      informed about their diagnoses, treatment procedures and goals of treatment. They also seek&#xD;
      active roles in decision-making. Shared decision-making (SDM) is the process of clinician and&#xD;
      patient jointly participating in a health decision after discussing the options, benefits and&#xD;
      harms, and considering the patient's values, preferences, and circumstances. SDM can improve&#xD;
      patient involvement in decision making, satisfaction, health care quality, and quality of&#xD;
      life. Decision aids can improve patient knowledge, create more realistic outcome&#xD;
      expectations; reduce decisional conflict, distress, depression and uncertainty; and improve&#xD;
      physician-patient communication and quality of life, compared with no decision aid. This&#xD;
      trial's main aim is to evaluate the feasibility and efficacy of a decision aid in patients&#xD;
      with non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Refine a conversation tool among patients with lung cancer by conducting prototype testing&#xD;
      in an iterative process.&#xD;
&#xD;
      II. Conduct a trial at two comprehensive cancer treatment centers representing academic and&#xD;
      Veterans Affairs medical centers.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive the conversation tool.&#xD;
&#xD;
      ARM II: Patients receive usual care.&#xD;
&#xD;
      Patients in both arms are followed up within 4-8 weeks after baseline to complete a second&#xD;
      questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of the conversation tool</measure>
    <time_frame>At enrollment</time_frame>
    <description>The number of patients enrolled divided by the number of patients offered enrollment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of the conversation tool</measure>
    <time_frame>At enrollment</time_frame>
    <description>Use the Ottawa Acceptability Tool to determine acceptability of the conversation tool.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>From enrollment to the end of follow-up at 8 weeks</time_frame>
    <description>Assessed using the Hospital Anxiety and Depression Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decisional conflict</measure>
    <time_frame>At the end of follow-up at 8 weeks</time_frame>
    <description>Assessed using the Decisional Conflict Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decisional Regret</measure>
    <time_frame>At the end of follow-up at 8 weeks</time_frame>
    <description>Assessed using the Decisional Regret Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived involvement in care</measure>
    <time_frame>At the end of follow-up at 8 weeks</time_frame>
    <description>Assessed using the Perceived Involvement in Care Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shared decision-making quality</measure>
    <time_frame>At the end of follow-up at 8 weeks</time_frame>
    <description>Assessed using the Shared Decision Making Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decision making involvement</measure>
    <time_frame>From enrollment to the end of follow-up at 8 weeks</time_frame>
    <description>Assessed using the Control Preferences Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-efficacy</measure>
    <time_frame>From enrollment to the end of follow-up at 8 weeks</time_frame>
    <description>Assessed using the Decision Self-Efficacy Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Values-treatment concordance</measure>
    <time_frame>From enrollment to the end of follow-up at 8 weeks</time_frame>
    <description>Assessed using electronic medical record (EMR).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lung Non-Small Cell Carcinoma</condition>
  <condition>Stage I Lung Cancer AJCC v8</condition>
  <condition>Stage IA1 Lung Cancer AJCC v8</condition>
  <condition>Stage IA2 Lung Cancer AJCC v8</condition>
  <condition>Stage IA3 Lung Cancer AJCC v8</condition>
  <condition>Stage IB Lung Cancer AJCC v8</condition>
  <condition>Stage II Lung Cancer AJCC v8</condition>
  <condition>Stage IIA Lung Cancer AJCC v8</condition>
  <condition>Stage IIB Lung Cancer AJCC v8</condition>
  <condition>Stage III Lung Cancer AJCC v8</condition>
  <condition>Stage IIIA Lung Cancer AJCC v8</condition>
  <condition>Stage IIIB Lung Cancer AJCC v8</condition>
  <condition>Stage IIIC Lung Cancer AJCC v8</condition>
  <condition>Stage IV Lung Cancer AJCC v8</condition>
  <condition>Stage IVA Lung Cancer AJCC v8</condition>
  <condition>Stage IVB Lung Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Arm I (conversation tool)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive the conversation tool.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (usual care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive usual care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Receive usual/standard of care</description>
    <arm_group_label>Arm II (usual care)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Informational Intervention</intervention_name>
    <description>Receive conversation tool</description>
    <arm_group_label>Arm I (conversation tool)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies - Baseline and follow-up questionnaires</description>
    <arm_group_label>Arm I (conversation tool)</arm_group_label>
    <arm_group_label>Arm II (usual care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PART I: Completed treatment for suspected or confirmed stage I-IV non-small cell lung&#xD;
             cancer (NSCLC)&#xD;
&#xD;
          -  PART I: English fluency&#xD;
&#xD;
          -  PART II: Undergoing diagnostic work-up for suspected stage I-IV NSCLC&#xD;
&#xD;
          -  PART II: English fluency&#xD;
&#xD;
          -  PART II: &gt; 6-month life expectancy&#xD;
&#xD;
          -  PART II: Score of &gt; 3 on the 6-Item Screener for Cognitive Impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Sullivan</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Sullivan</last_name>
      <phone>503-220-8262</phone>
      <phone_ext>58087</phone_ext>
      <email>sullivad@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Donald Sullivan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Portland VA Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Sullivan</last_name>
      <phone>503-220-8262</phone>
      <phone_ext>58087</phone_ext>
      <email>sullivad@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Donald Sullivan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Donald R Sullivan, MD, MA, MCR</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

